Looking to sell Immunai stock or options?Contact us
Immunai, a developer of immune system technology, is aimed at providing treatments for oncology and auto-immune disorders. The company's platform merges comprehensive mapping and reprogramming of the immune system with single-cell biology, AI, and machine learning. This provides novel insights into the immune system and enables healthcare researchers to speed up drug development and enhance patient outcomes.
Meron Capital, 8VC, Alexandria Venture Investments, Gefen Capital, Perot Jain, Dexcel Pharma, Piedmont Capital Investments, Talos Ventures, Duquesne Family Office, iAngels, TLV Partners, Schusterman Family Investments, ICON (Palo Alto), R-Squared Ventures, Koch Disruptive Technologies, Gad Allon, Piedmont, Viola Ventures, Catalio Capital Management.
We have an even better solution: The Collective Exchange Fund
Get in touch and see if we can help you